Lanean...
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia
Tyrosine kinase inhibitors (TKIs) directed against the ABL kinase are now used routinely during frontline therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and result in hematologic remission rates exceeding 90%. Minimal residual disease levels are generally lower wh...
Gorde:
| Argitaratua izan da: | Leukemia Suppl |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group
2012
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4851212/ https://ncbi.nlm.nih.gov/pubmed/27175253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leusup.2012.7 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|